Genetic Biomarkers of Executive Stress

July 18, 2017 updated by: Natalie Rasgon, Stanford University
The purpose of this study is to examine whether stress predicts telomere length in individuals who hold executive-level positions. Telomeres are the caps at the end of each strand of DNA that may affect how cells age. Subjects will complete an online survey/interview and provide one blood sample or saliva samples. The goal is to understand whether stress predicts genetic markers of longevity.

Study Overview

Status

Completed

Conditions

Detailed Description

The primary aim of this study is to evaluate the relationship between overall levels of stress and telomere length. It is hypothesized that the high stress group (based on the Perceived Stress Scale)compared to low stress group will have shorter telomere length. A secondary aim is to evaluate whether different types of stress have differing degrees of association with telomere length. An exploratory aim is to assess for gender differences in the association between stress and telomere length. The investigators are collecting a number of other measures, including demographics, work sector, perceived social support, and medical history, in order to adjust for potential confounders in the analysis.

This study is an extension of earlier work Dr. Rasgon has done with Dr. Elizabeth Blackburn at UCSF on the relationship between telomere length and mood outcomes. The investigators hope this study will add to the growing body of literature on stress and genetic markers of longevity, specifically how stress level and type is associated with telomere length. The increased understanding gained through this study may provide leads for predicting age-related diseases and early mortality in adults, thus benefiting others in the future.

Study Type

Observational

Enrollment (Actual)

51

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Stanford, California, United States, 94305
        • Stanford University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

100 subjects - individuals who hold executive-level positions. Participants are males and females, 18 or older, may be of any ethnic background. The investigators aim to recruit a diverse sample, reflective of the broader population.

Description

Inclusion Criteria:

  1. People of either gender >18 years of age.
  2. Subject hold executive-level position as defined as meeting the following criteria: having managerial responsibility over an organization or substantial part of an organization and/or having strategic influence over the direction of the organization
  3. Subject or representative is willing to sign the consent for prior to enrollment into the study, and to participate in all aspects of the study. Prospective subject must give verbal assent if unable to sign written consent.
  4. Adequate visual acuity to complete questionnaires.

Exclusion Criteria:

  1. Subjects will be excluded if they have any of the following medical conditions:

    1. active heart disease
    2. acute psychiatric disorder (hospitalized in the past year)
    3. any medical condition deemed exclusionary by the Principal Investigator (PI)
  2. Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within one year prior to screening.
  3. Subject is currently taking any medication deemed exclusionary by PI.
  4. Subject is pregnant, lactating, or planning to become pregnant during the study period.
  5. Subject is participating or has participated in another research study within 30 days prior to the screening visit.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Telomere Length
Time Frame: 1 day
Subjects will come in for 1 visit to give a saliva or blood sample which will be used to measure telomere length.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Natalie Rasgon, M.D., Ph.D., Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2015

Primary Completion (Actual)

June 1, 2017

Study Completion (Actual)

June 1, 2017

Study Registration Dates

First Submitted

October 12, 2016

First Submitted That Met QC Criteria

October 12, 2016

First Posted (Estimate)

October 14, 2016

Study Record Updates

Last Update Posted (Actual)

July 21, 2017

Last Update Submitted That Met QC Criteria

July 18, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 35668

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

3
Subscribe